Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Amgen presents survival data from Phase 3 study of talimogene laherparepvec
Amgen presents survival data from Phase 3 study of talimogene laherparepvec
Amgen presents survival data from Phase 3 study of talimogene laherparepvec
Submitted by
admin
on November 18, 2013 - 4:39pm
Source:
Yahoo/Fly on the Wall
News Tags:
Amgen
Talimogene Laherparepvec
melanoma
Headline:
Amgen presents survival data from Phase 3 study of talimogene laherparepvec
Do Not Allow Advertisers to Use My Personal information
